Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Triple Negative Breast Neoplasms

ClinicalTrials.gov lists 1,193 trials for Triple Negative Breast Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 45.

MeSH D064726 Neoplasms Neoplasm C04 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 311 Phase 1/2 Phase 1/2 175 Phase 2 Phase 2 418 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 90 Phase 4 Phase 4 6 Not applicable Not applicable 71 Observational Observational 107 Phase 1 Phase 1 311 Phase 1/2 Phase 1/2 175 Phase 2 Phase 2 418 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 90 Phase 4 Phase 4 6 Not applicable Not applicable 71 Observational Observational 107

Trials per phase (log scale)

1 more section with rows

1,193 of the 1,193 trials are tagged with Triple Negative Breast Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Triple Negative Breast Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Triple Negative Breast Neoplasms trials start? (23)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 117

1996: 1 trials (Observational 1) 2000: 1 trials (Phase 3 1) 2001: 1 trials (Phase 1 1) 2007: 3 trials (Phase 2 3) 2008: 9 trials (Observational 1, Phase 2 4, Phase 1 4) 2009: 11 trials (Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 4) 2010: 27 trials (Observational 3, Phase 3 2, Phase 2 10, Phase 1/2 2, Phase 1 10) 2011: 24 trials (Observational 3, Not applicable 2, Phase 3 3, Phase 2 8, Phase 1 8) 2012: 20 trials (Not applicable 2, Phase 3 1, Phase 2 10, Phase 1/2 2, Phase 1 5) 2013: 23 trials (Observational 4, Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 3, Phase 1 6) 2014: 23 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 8, Phase 1/2 1, Phase 1 8) 2015: 48 trials (Observational 1, Not applicable 4, Phase 4 1, Phase 3 5, Phase 2 16, Phase 1/2 7, Phase 1 14) 2016: 65 trials (Not applicable 1, Phase 3 6, Phase 2/3 2, Phase 2 20, Phase 1/2 10, Phase 1 26) 2017: 82 trials (Observational 5, Not applicable 7, Phase 3 5, Phase 2 29, Phase 1/2 13, Phase 1 23) 2018: 72 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2 23, Phase 1/2 15, Phase 1 22) 2019: 87 trials (Observational 8, Not applicable 3, Phase 3 5, Phase 2/3 1, Phase 2 27, Phase 1/2 14, Phase 1 29) 2020: 84 trials (Observational 6, Not applicable 3, Phase 3 8, Phase 2 30, Phase 1/2 13, Phase 1 24) 2021: 88 trials (Observational 11, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 38, Phase 1/2 14, Phase 1 16) 2022: 93 trials (Observational 8, Not applicable 3, Phase 3 7, Phase 2/3 1, Phase 2 35, Phase 1/2 20, Phase 1 19) 2023: 81 trials (Observational 12, Not applicable 4, Phase 4 1, Phase 3 7, Phase 2 19, Phase 1/2 16, Phase 1 22) 2024: 117 trials (Observational 10, Not applicable 7, Phase 3 8, Phase 2 47, Phase 1/2 14, Phase 1 31) 2025: 105 trials (Observational 14, Not applicable 11, Phase 4 1, Phase 3 8, Phase 2/3 2, Phase 2 37, Phase 1/2 10, Phase 1 22)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 117
2025 105
2024 117
2023 81
2022 93
2021 88
2020 84
2019 87
2018 72
2017 82

Showing 10 of 23 earlier years.

Start your 14-day trial Email me all 23 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 130 trials starting in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 310 trials still running at the 2026-10-09 snapshot; registered median of 39 months across 520 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Triple Negative Breast Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 311
Phase 1/2 175
Phase 2 418
Phase 2/3 9
Phase 3 90
Phase 4 6
Not applicable 71
Observational 107
Expanded access 6

How many Triple Negative Breast Neoplasms trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 93
Recruiting 306
Enrolling by invitation 4
Active, not recruiting 143
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Triple Negative Breast Neoplasms trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 45
Novartis Pharmaceuticals 21
AstraZeneca 14
Merck Sharp & Dohme LLC 14
Gilead Sciences 11

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Triple Negative Breast Neoplasms? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 157
(nab)-paclitaxel 107
Cytoxan 83
NAB paclitaxel 64
"Capecitabine" 52

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
or carboplatin 116
Doxorubicine 41
Gemcitabine/Gemzar 38
Sacituzumab Govitecan-hiy 32
Atezolizumab SC 31

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Triple Negative Breast Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 397 70
Febrile neutropenia 325 55
Pyrexia 318 65
Nausea 284 84
Pleural effusion 281 76

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Triple Negative Breast Neoplasms? (524)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030). Journal of the National Cancer Institute 2026 Yes
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Yes
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. The New England journal of medicine 2026 Yes
Immune-modulatory effects of low-dose radiotherapy through macrophage polarization and transcriptional rewiring in triple-negative breast cancer. Biochemical and biophysical research communications 2025 Yes
Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiology. Artificial intelligence 2025 Yes

Showing 5 of 524 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages